Browse the evidence

PGC-1α plays an important role in skeletal muscle ROS balance through the regulation of anti-oxidant proteins and proton leak.

Exercise that boosts PGC-1α may help manage oxidative stress by enhancing anti-oxidant defenses and reducing proton leak.

Acute sleep deprivation (64 hours) induces physiologic leukocytosis and increases Natural Killer (NK) cell activity, which parallels neurobehavioral fatigue and is reversed by recovery sleep.

Getting less than 8 hours of sleep for a few days doesn't necessarily 'weaken' your immune system in the way people fear. Instead, your body actively mobilizes immune cells (like NK cells and white blood cells) in response to the stress of being awake. This mobilization tracks with how tired you feel. Prioritizing recovery sleep is essential to normalize these levels, as the immune boost disappears once you recover.

Age-related early morning awakening and reduced sleep consolidation are driven by an internal phase advance of the circadian pacemaker and a reduction in the amplitude of the endogenous circadian component of core body temperature, rather than a shortening of the intrinsic circadian period.

If you are older and waking up very early, it is likely due to a shift in your internal biological timing and a weaker sleep drive, not necessarily a 'broken' or 'fast' clock. You can potentially reinforce a later wake time by exposing yourself to bright light in the early morning, which helps anchor the circadian phase later.

The amplitude of the endogenous circadian component of core body temperature is significantly reduced in older adults compared to young adults, contributing to reduced sleep consolidation.

Older adults often have a weaker internal signal for sleep, reflected in a smaller daily fluctuation in body temperature. This weaker signal makes it harder to stay asleep, especially in the early morning hours.

Sleep homeostatic mechanisms, specifically the increase in EEG slow-wave activity (SWA) following sleep deprivation, remain operative in older adults, although baseline and recovery SWA levels are lower than in young adults.

Older adults still build up sleep pressure (homeostasis) effectively, but the resulting deep sleep (SWA) is less intense than in youth. This contributes to fragmented sleep.

Skeletal muscle-specific overexpression of Carnitine Palmitoyltransferase-1 (CPT1) enhances fatty acid oxidation and ameliorates high-fat diet-induced insulin resistance by reducing intramuscular lipid accumulation and inflammatory signaling.

This research suggests that improving the muscle's capacity to transport fatty acids into mitochondria (via CPT1 activity) can reverse insulin resistance caused by a high-fat diet. This is achieved not by blocking fat entry, but by ensuring it is oxidized, which reduces harmful lipid byproducts like diacylglycerol (DAG) that interfere with insulin signaling. While this was achieved via genetic overexpression in rats, it supports the broader principle that enhancing mitochondrial fatty acid flux may be beneficial for insulin sensitivity in the context of high lipid intake.

Erythropoiesis-stimulating agents (epoetin alfa, epoetin beta, and darbepoetin alfa) effectively improve haematological response and reduce red blood cell transfusion requirements in cancer patients with anaemia, but do not provide a survival advantage and may increase the risk of thrombotic events.

For cancer patients with anaemia, epo drugs effectively raise hemoglobin and reduce the need for blood transfusions, improving quality of life. However, they do not extend life and may increase clotting risks. Treatment decisions should weigh these benefits against the lack of survival advantage and potential side effects, adhering to safety guidelines that limit use in patients with higher baseline hemoglobin levels.

In humans, adipose tissue is the predominant source of serum amyloid A (A-SAA), and elevated A-SAA levels in obesity drive systemic inflammation and insulin resistance through the stimulation of proinflammatory cytokines and increased lipolysis.

This research highlights that obesity is not just about excess fat mass but involves active hormonal signaling from fat cells that drives inflammation and insulin resistance. Specifically, fat cells in obese individuals produce high levels of Serum Amyloid A (A-SAA), which triggers inflammatory responses and increases fat breakdown (lipolysis), contributing to metabolic issues. Weight loss significantly reduces these A-SAA levels, which correlates with improved insulin sensitivity. This suggests that treating obesity involves resolving this specific inflammatory signaling pathway, not just reducing energy storage.

Rosiglitazone treatment reduces serum A-SAA levels and adipose A-SAA secretion in obese individuals independent of changes in body weight or fat mass.

This study shows that the drug rosiglitazone can significantly reduce inflammatory markers (A-SAA) in obese individuals without requiring weight loss. This suggests that some medications target specific inflammatory pathways in fat tissue directly. While this is a specific drug finding, it underscores that metabolic health involves complex hormonal signaling that can be modulated pharmacologically, independent of simple caloric balance.

The insulin receptor isoform IR-A, which binds IGF-2 and proinsulin, promotes cell proliferation and is associated with detrimental effects like cancer progression and insulin resistance when overexpressed in adult life, whereas IR-B is primarily responsible for metabolic regulation.

This research highlights that not all insulin signaling is the same. The IR-A isoform, which responds to IGF-2 and proinsulin, drives cell growth and is linked to cancer and insulin resistance when overactive in adults. In contrast, IR-B handles metabolic regulation. Future treatments may need to target specific isoforms to manage diabetes without promoting cancer risk, suggesting that precision medicine approaches are necessary for metabolic health.

Proinsulin acts as a selective ligand for the IR-A isoform, stimulating cell proliferation and migration with an affinity similar to IGF-2, thereby contributing to the mitogenic effects of hyperproinsulinemia.

High levels of proinsulin, often seen in early type 2 diabetes, are not just a byproduct of metabolic dysfunction but actively stimulate cell growth by binding to the IR-A receptor. This mechanism links metabolic disorders to increased cancer risk, suggesting that managing proinsulin levels is crucial for preventing proliferative diseases.

Physical activity induces epigenetic modifications, including DNA methylation and histone modifications, which can alter gene expression related to mitochondrial function and brain plasticity, potentially creating an 'epigenetic memory' that affects long-term brain health.

Regular physical activity can change how your genes are expressed, potentially protecting your brain against aging and diseases like Alzheimer's. This happens through epigenetic changes that your body makes in response to exercise.

Supplemental intakes of EPA and DHA combined up to 5 g/day do not significantly affect glucose homeostasis in healthy or diabetic subjects.

If you have diabetes or are healthy, taking up to 5g/day of combined EPA/DHA will not negatively affect your blood sugar control. You can take this dose without worrying about glucose homeostasis.

High estrogen levels during the ovulatory phase of the menstrual cycle decrease ligament stiffness by inhibiting lysyl oxidase activity, leading to increased knee laxity and a significantly higher risk of anterior cruciate ligament (ACL) injury.

Female athletes should be aware that their risk of ACL injury increases during the ovulatory phase of their menstrual cycle due to hormonal changes that loosen ligaments. While you cannot change your hormones, you can adjust training loads or focus on neuromuscular control exercises during this high-risk window to mitigate the increased laxity.

High estrogen levels decrease tendon stiffness by inhibiting lysyl oxidase activity, which may protect muscles from eccentric injury but can negatively impact performance by reducing power output.

High estrogen levels make your tendons more compliant, which can protect your muscles from strain injuries during exercise. However, this same compliance might reduce your power output. Balance your training to account for these changes.

Activation of SIRT1 reduces hepatic steatosis by deacetylating and inhibiting lipogenic transcription factors SREBP-1c and ChREBP, while simultaneously enhancing fatty acid beta-oxidation via PPARalpha/PGC-1alpha signaling.

SIRT1 is a metabolic sensor that helps the liver manage fat. It works by turning down fat production genes and turning up fat-burning genes. While activating SIRT1 (e.g., via calorie restriction or specific compounds) shows protective effects in animal models, it is not a standalone cure. The primary driver of fatty liver remains the imbalance of lipid acquisition (diet/alcohol) versus removal.

Acute moderate-intensity exercise does not significantly alter postprandial ghrelin levels in normal-weight subjects, suggesting ghrelin is not the primary driver of exercise-induced appetite suppression.

Don't blame ghrelin for your hunger (or lack thereof) after a moderate workout. Your body uses other signals (PYY, GLP-1) to manage appetite.

Vitamin D supplementation does not significantly improve glycaemic control (HbA1c) or insulin resistance in patients with normal fasting glucose, and provides only a small, likely clinically insignificant reduction in fasting glucose for those with diabetes or impaired glucose tolerance.

If you have diabetes or pre-diabetes, taking Vitamin D supplements is unlikely to significantly lower your blood sugar or HbA1c levels. While there might be a tiny reduction in fasting glucose for some, it is not clinically significant enough to rely on as a treatment. Focus on proven methods like diet, exercise, and prescribed medication instead.

Chronic high-fructose consumption promotes hepatic de novo lipogenesis (DNL) and intrahepatic lipid accumulation primarily by bypassing rate-limiting glycolytic steps and activating transcription factors ChREBP and SREBP1c, leading to increased VLDL secretion and dyslipidemia.

Fructose metabolism uniquely stimulates liver fat production through specific biological pathways (ChREBP/SREBP1c). However, human studies show that if you replace other calories with fructose without gaining weight (isocaloric), your liver fat may not increase more than if you ate those other calories. The real danger of fructose is that it contributes to excess calorie intake and weight gain. Focus on total caloric balance first; reducing high-fructose corn syrup and added sugars is a smart move for weight management, but don't assume fructose alone causes fatty liver if you are in a caloric deficit.

Fasting plasma concentrations of alpha-hydroxybutyrate (a-HB) and linoleoyl-glycerophosphocholine (L-GPC) serve as independent, early metabolic markers for predicting the development of dysglycemia and type 2 diabetes, with high a-HB and low L-GPC levels indicating increased risk.

If you are at risk for type 2 diabetes, standard fasting glucose tests might miss early metabolic changes. Emerging research suggests that specific metabolites (alpha-hydroxybutyrate and linoleoyl-glycerophosphocholine) can predict the development of diabetes earlier than standard tests. While not yet routine, these markers reflect underlying insulin resistance and beta-cell stress, suggesting that early metabolic profiling could allow for earlier lifestyle or medical interventions before glucose levels become abnormal.

Metformin's primary glucose-lowering mechanism involves altering gut microbiota composition to increase butyrate and propionate production and enhance GLP-1 secretion, rather than solely acting via hepatic pathways.

If you take metformin, its effectiveness is partly driven by how it changes your gut bacteria to boost GLP-1. If you experience stomach issues, ask about delayed-release formulations (MetDR) which target the lower gut specifically, potentially reducing side effects while maintaining efficacy.

Fasting and calorie restriction upregulate UCP2 and UCP3 mRNA expression in human skeletal muscle and adipose tissue, suggesting a metabolic adaptation to energy deficit.

When you restrict calories, your body increases the expression of specific mitochondrial proteins (UCP2 and UCP3) in muscle and fat. This is a normal adaptation to fasting, not a sign that your metabolism is permanently broken. This upregulation happens similarly in both lean and obese individuals, suggesting the regulatory machinery is intact even in obesity.

TLR4 signaling is a key pathway for the progression of NAFLD, driven by circulating LPS from gut microbiota.

Focus on reducing gut permeability through diet (e.g., fiber, probiotics) to lower LPS levels, which may reduce liver inflammation via the TLR4 pathway.

Aging has a profound impact on the regulation of satellite cells in human skeletal muscle, potentially leading to a decrease in satellite cell number and function.

As you age, your satellite cells may not function as well, but you can still build muscle through exercise and proper nutrition. Focus on resistance training and a balanced diet to support muscle growth and adaptation.